Pseudoprogression and Treatment Effect
Section snippets
Pseudoprogression: early transient enhancing lesions
Pseudoprogression is defined as enhancing changes seen on MRI within the first 3 months after treatment of glioblastoma with fractionated radiotherapy. Pseudoprogression represents treatment effects rather than treatment failure, which, with time, either successively recovers or stabilizes without being linked to subordinate outcomes.14 Since postoperative radiotherapy and concomitant temozolomide were established as the standard treatment of glioblastoma, there has been an increase in
Radiation necrosis: delayed enhancing lesions
Since the randomized clinical trials in the 1970s demonstrating an improvement in overall survival, postoperative whole-brain radiotherapy at a daily dose of 2 Gy per fraction given over a 6-week period for a total dose of 60 Gy has become part of the standard treatment of glioblastoma.3, 27 Patients treated with radiation therapy in this manner often exhibit enhancement in radiation within 3 to 12 months of completing radiation. This phenomenon is called radiation necrosis and is now a common
Antiangiogenic therapy for glioblastoma: radiologic and nonradiologic biomarkers of efficacy
Bevacizumab, a monoclonal anti-VEGF antibody, has been studied in phase II trials of patients with recurrent glioblastoma and demonstrated a 23-week medial progression-free survival when administered in combination with irinotecan.8, 9 A study of patients with glioblastoma treated with bevacizumab revealed decreased tumor hypoxia and increased tumoral VEGF expression, which were directly associated with radiographic response and prolonged survival following treatment.55
VEGF levels have been
Response assessment in neuro-oncology criteria for high-grade gliomas
Until recently, the MacDonald Criteria,13 first published in 1990, served as the standard for determining response assessment in high-grade gliomas. It provided an objective radiologic assessment of the tumor response based primarily on 2-dimensional enhancing tumor area deriving from contrast-enhanced computed tomography.70 The use of corticosteroids and fluctuations in patients’ neurologic status were also taken into consideration. The Macdonald criteria were also further applied to MRI,
Distinguishing treatment effect or pseudoprogression from true progression
Conventional MRI with gadolinium contrast enhancement fails to differentiate between true tumor recurrence, pseudoprogression, or radiation necrosis.14, 29, 37, 73 This form of imaging is also unable to distinguish true treatment response from the anti-VEGF treatment’s impact at palliating radiation necrosis, a distinction that is important because anti-VEGF is used more commonly with drugs, such as bevacizumab.69 Although new studies have suggested findings on conventional MRI, such as
Summary
The postoperative administration of adjuvant temozolomide and radiation is the new standard of care in patients with newly diagnosed glioblastoma. Pseudoprogression and radiation necrosis are common treatment effects that add much confusion in the detection of tumor recurrence using conventional MRI with gadolinium enhancement. These challenges are confounded with the recent increasing use of antiangiogenic therapy to treat newly diagnosed and recurrent glioblastoma. Until randomized trials
References (99)
- et al.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Lancet Oncol
(2009) - et al.
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma
Int J Radiat Oncol Biol Phys
(2010) - et al.
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide
Clin Neurol Neurosurg
(2010) - et al.
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Lancet Oncol
(2008) - et al.
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
Lab Invest
(2007) - et al.
Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging
Acad Radiol
(2011) - et al.
Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume
Int J Radiat Oncol Biol Phys
(1981) - et al.
Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy
Int J Radiat Oncol Biol Phys
(2006) - et al.
Radiation dose-volume effects in the brain
Int J Radiat Oncol Biol Phys
(2010) - et al.
Therapeutic irradiation and brain injury
Int J Radiat Oncol Biol Phys
(1980)
Role of acidic sphingomyelinase in Fas/CD95-mediated cell death
J Biol Chem
Responses of normal cells to ionizing radiation
Semin Radiat Oncol
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
Am J Pathol
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Cancer Cell
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
Neoplasia
Effect of bevacizumab on radiation necrosis of the brain
Int J Radiat Oncol Biol Phys
Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI
Clin Neurol Neurosurg
Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions
Magn Reson Imaging
Multiparametric tissue characterization of brain neoplasms and their recurrence using pattern classification of MR images
Acad Radiol
Diffusion and diffusion tensor imaging in brain cancer
Semin Radiat Oncol
Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging
Int J Radiat Oncol Biol Phys
Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study
Int J Radiat Oncol Biol Phys
Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy
Neurosurg Clin N Am
Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment
Neurosurgery
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
N Engl J Med
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status
J Clin Oncol
A novel tool to analyze MRI recurrence patterns in glioblastoma
Neuro Oncol
Glioblastoma: patterns of recurrence and efficacy of salvage treatments
Can J Neurol Sci
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
Clin Cancer Res
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
J Clin Oncol
Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment
Radiology
Cerebral radiation necrosis
Neurologist
Response criteria for phase II studies of supratentorial malignant glioma
J Clin Oncol
Mechanisms of radiation injury to the central nervous system: implications for neuroprotection
Mol Interv
New advances that enable identification of glioblastoma recurrence
Nat Rev Clin Oncol
The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas
Clin Oncol (R Coll Radiol)
Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
Neurology
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
J Clin Oncol
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Cancer
Temozolomide: a novel oral alkylating agent
Expert Rev Anticancer Ther
MGMT gene silencing and benefit from temozolomide in glioblastoma
N Engl J Med
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms
Clin Cancer Res
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients
Neuro Oncol
Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences
Nucleic Acids Res
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial
J Neurosurg
Dynamic magnetic resonance perfusion imaging of brain tumors
Oncologist
The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study
Prog Exp Tumor Res
Brain tumors
N Engl J Med
Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study
AJNR Am J Neuroradiol
Cited by (25)
Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 – Radiological features and metric markers
2021, Critical Reviews in Oncology/HematologyCitation Excerpt :Advanced MRI techniques can provide additional information when conventional MRI is ambiguous to improve the distinction between PsP and TP (Masch et al., 2016; Gerstner et al., 2009). Different diffusion modalities and metrics were developed (Table 1) (Jahangiri and Aghi, 2012; Zhang et al., 2016; Verma et al., 2008). Radiation injury images usually show heterogeneity on DWI images and often include spotty and marked hypointensity (Asao et al., 2005).
Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 – Molecular, morphological and clinical features
2021, Critical Reviews in Oncology/HematologyCitation Excerpt :Usually, PsP is a subacute secondary effect of treatment that is clinically asymptomatic and mimics progression (Brandsma et al., 2008; Hygino da Cruz et al., 2011; Jefferies et al., 2007). PsP reflects the response to treatment rather than treatment failure (Jahangiri and Aghi, 2012). The definition of PsP can include a component of clinical impairment, but its appreciation remains variable and blurry.
21 - Therapy-Associated Neuropathology
2018, Practical Surgical Neuropathology: A Diagnostic Approach A Volume in the Pattern Recognition SeriesDiagnostic Imaging: Brain
2016, Diagnostic Imaging: BrainImaging in Neurology
2016, Imaging in NeurologyComparison of diffusion tensor, dynamic susceptibility contrast MRI and <sup>99m</sup>Tc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma
2014, Magnetic Resonance ImagingCitation Excerpt :Over the past decade progress has been made in the treatment of high-grade glioma, and the reported 2-year survival rate of patients with GBM in research studies increased from 10% in 2000 to nearly 40% in 2010 [10]. In parallel, there has been an increase in the detection on MRI of enhancing and progressive lesions following treatment, giving rise to the clinical dilemma of whether these are due to treatment induced necrosis or tumor recurrence [11]. A correct diagnosis is crucial since the two entities have a different prognosis and require different management.